<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03928522</url>
  </required_header>
  <id_info>
    <org_study_id>201811101</org_study_id>
    <nct_id>NCT03928522</nct_id>
  </id_info>
  <brief_title>Antibiotic Elution in Total Knee Arthroplasty</brief_title>
  <official_title>Prospective Randomized Study Investigating the Characterization of Antibiotics From Antibiotic Impregnated Cement After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to characterize and quantify the level of antibiotics eluted from&#xD;
      antibiotic laden cement after primary cemented total knee arthroplasty.&#xD;
&#xD;
      Patients will be identified by medical record review to make sure they meet inclusion and&#xD;
      exclusion criteria.&#xD;
&#xD;
      Patients that qualify and sign consent will be randomized to 1 of 4 antibiotic cement groups&#xD;
      which are pre-mixed tobramycin, hand-mixed tobramycin, hand mixed vancomycin, and hand-mixed&#xD;
      tobramycin and hand mixed vancomycin. Study patients will be blinded to their study group.&#xD;
      Intraoperative fluid from the knee prior to surgery and postoperative drain fluid from the&#xD;
      knee postoperatively will be collected as well.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be identified by medical record review to make sure they meet inclusion and&#xD;
      exclusion criteria.&#xD;
&#xD;
      Patients that qualify and sign consent will be randomized to 1 of 4 antibiotic cement groups&#xD;
      which are pre-mixed tobramycin, hand-mixed tobramycin, hand mixed vancomycin, and hand-mixed&#xD;
      tobramycin and hand mixed vancomycin. Study patients will be blinded to their study group.&#xD;
      Intraoperative fluid from the knee prior to surgery and postoperative drain fluid from the&#xD;
      knee postoperatively will be collected as well.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 28, 2019</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>patient will not know which antibiotic cement group they are in</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty</measure>
    <time_frame>24 hours</time_frame>
    <description>We wanted to measure the effect of elution level of vancomycin and tobramycin together</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Total Knee Replacement</condition>
  <arm_group>
    <arm_group_label>Pre-mixed tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive pre-mixed tobramycin cement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hand mixed tobramycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive hand mixed tobramycin cement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hand mixed vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive hand mixed vancomycin cement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hand-mixed vancomycin and tobramycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive hand mixed vancomycin and tobramycin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hand mixed vancomycin</intervention_name>
    <description>hand mixed vancomycin powder into cement</description>
    <arm_group_label>hand mixed vancomycin</arm_group_label>
    <arm_group_label>hand-mixed vancomycin and tobramycin</arm_group_label>
    <other_name>Vancomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hand mixed tobramycin</intervention_name>
    <description>hand mixed tobramycin into cement</description>
    <arm_group_label>hand mixed tobramycin</arm_group_label>
    <arm_group_label>hand-mixed vancomycin and tobramycin</arm_group_label>
    <other_name>Tobramycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>pre-mixed tobramycin</intervention_name>
    <description>this cement is already pre-mixed with tobramycin</description>
    <arm_group_label>Pre-mixed tobramycin</arm_group_label>
    <other_name>Antibiotic PMMA bone cement</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age over 18&#xD;
&#xD;
          -  Total knee arthroplasty for primary osteoarthritis performed by Dr. Rick Wright.&#xD;
&#xD;
          -  Primary diagnosis of knee osteoarthritis&#xD;
&#xD;
               -  Exclusion Criteria:&#xD;
&#xD;
          -  Diminished mental capacity&#xD;
&#xD;
          -  Vancomycin allergy&#xD;
&#xD;
          -  Tobramycin allergy&#xD;
&#xD;
          -  Patient history requiring IV administration of vancomycin or tobramycin&#xD;
             perioperatively&#xD;
&#xD;
          -  Chronic kidney disease stage III and stage IV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Lawrie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University Orthopedics</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2019</study_first_posted>
  <results_first_submitted>September 14, 2020</results_first_submitted>
  <results_first_submitted_qc>October 8, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2020</results_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 8, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/22/NCT03928522/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Pre-mixed Tobramycin</title>
          <description>patients will receive pre-mixed tobramycin cement&#xD;
pre-mixed tobramycin: this cement is already pre-mixed with tobramycin</description>
        </group>
        <group group_id="P2">
          <title>Hand Mixed Tobramycin</title>
          <description>patients will receive hand mixed tobramycin cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="P3">
          <title>Hand Mixed Vancomycin</title>
          <description>patients will receive hand mixed vancomycin cement&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement</description>
        </group>
        <group group_id="P4">
          <title>Hand-mixed Vancomycin and Tobramycin</title>
          <description>patients will receive hand mixed vancomycin and tobramycin&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="P5">
          <title>Intra-articular Vancomycin</title>
          <description>Patients will receive powdered vancomycin antibiotic into a cementless total knee in wound prior to closure</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pre-mixed Tobramycin</title>
          <description>patients will receive pre-mixed tobramycin cement&#xD;
pre-mixed tobramycin: this cement is already pre-mixed with tobramycin</description>
        </group>
        <group group_id="B2">
          <title>Hand Mixed Tobramycin</title>
          <description>patients will receive hand mixed tobramycin cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="B3">
          <title>Hand Mixed Vancomycin</title>
          <description>patients will receive hand mixed vancomycin cement&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement</description>
        </group>
        <group group_id="B4">
          <title>Hand-mixed Vancomycin and Tobramycin</title>
          <description>patients will receive hand mixed vancomycin and tobramycin&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="B5">
          <title>Intr-articular Vancomycin</title>
          <description>Patients will receive powdered vancomycin antibiotic into a cementless total knee in wound prior to closure</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty</title>
        <description>We wanted to measure the effect of elution level of vancomycin and tobramycin together</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-mixed Tobramycin</title>
            <description>patients will receive pre-mixed tobramycin cement&#xD;
pre-mixed tobramycin: this cement is already pre-mixed with tobramycin</description>
          </group>
          <group group_id="O2">
            <title>Hand Mixed Tobramycin</title>
            <description>patients will receive hand mixed tobramycin cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
          </group>
          <group group_id="O3">
            <title>Hand Mixed Vancomycin</title>
            <description>patients will receive hand mixed vancomycin cement&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement</description>
          </group>
          <group group_id="O4">
            <title>Hand-mixed Vancomycin and Tobramycin</title>
            <description>patients will receive hand mixed vancomycin and tobramycin&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
          </group>
          <group group_id="O5">
            <title>Intr-articular Vancomycin</title>
            <description>Patients will receive powdered vancomycin antibiotic into a cementless total knee in wound prior to closure</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Vancomycin and Tobramycin Eluted From Hand Mixed Cement With Both Antibiotics After Total Knee Arthroplasty</title>
          <description>We wanted to measure the effect of elution level of vancomycin and tobramycin together</description>
          <units>mg/mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" lower_limit="9.8" upper_limit="125.4"/>
                    <measurement group_id="O2" value="30.6" lower_limit="8.6" upper_limit="81.0"/>
                    <measurement group_id="O3" value="12.6" lower_limit="2.0" upper_limit="72.6"/>
                    <measurement group_id="O4" value="16.2" lower_limit=".3" upper_limit="47.3"/>
                    <measurement group_id="O5" value="1315" lower_limit="429" upper_limit="2324.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected within 4-6 weeks after surgery.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pre-mixed Tobramycin</title>
          <description>patients will receive pre-mixed tobramycin cement&#xD;
pre-mixed tobramycin: this cement is already pre-mixed with tobramycin</description>
        </group>
        <group group_id="E2">
          <title>Hand Mixed Tobramycin</title>
          <description>patients will receive hand mixed tobramycin cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="E3">
          <title>Hand Mixed Vancomycin</title>
          <description>patients will receive hand mixed vancomycin cement&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement</description>
        </group>
        <group group_id="E4">
          <title>Hand-mixed Vancomycin and Tobramycin</title>
          <description>patients will receive hand mixed vancomycin and tobramycin&#xD;
hand mixed vancomycin: hand mixed vancomycin powder into cement&#xD;
hand mixed tobramycin: hand mixed tobramycin into cement</description>
        </group>
        <group group_id="E5">
          <title>Intra-articular Vancomycin</title>
          <description>patients will receive powdered vancomycin into the wound before closure</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Venessa Riegler</name_or_title>
      <organization>Washington University</organization>
      <phone>314-362-1721</phone>
      <email>rieglerv@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

